Zaloguj Zarejestruj się zadarmo

Last updated: 4 January 2024 at 4:10pm EST

Frank Morich Net Worth




The estimated Net Worth of Frank Morich is at least $94.8 Tysiąc dollars as of 27 May 2022. Frank Morich owns over 28,000 units of Cue Biopharma Inc stock worth over $16,520 and over the last 6 years he sold CUE stock worth over $0. In addition, he makes $78,256 as Independent Chairman of the Board at Cue Biopharma Inc.

Frank Morich CUE stock SEC Form 4 insiders trading

Frank has made over 1 trades of the Cue Biopharma Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 28,000 units of CUE stock worth $105,000 on 27 May 2022.

The largest trade he's ever made was buying 28,000 units of Cue Biopharma Inc stock on 27 May 2022 worth over $105,000. On average, Frank trades about 2,800 units every 0 days since 2018. As of 27 May 2022 he still owns at least 28,000 units of Cue Biopharma Inc stock.

You can see the complete history of Frank Morich stock trades at the bottom of the page.





Frank Morich biography

Dr. Frank Morich M.D., Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Morich joined our board of directors in July 2018 and was appointed Chairman in April 2020. Dr. Morich serves as a consultant in the life sciences and health care industries. Dr. Morich has been a member of the supervisory board of MorphoSys AG (Nasdaq: MOR), a late-stage, biopharmaceutical company, since 2015. From 2011 to 2014, Dr. Morich served as Chief Commercial Officer at Takeda Pharmaceutical, a global pharmaceutical company, and from 2010 to 2011, he served as Executive Vice President International Operations at Takeda. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical-stage drug development company, and from 2005 to 2007 he served as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. During 2004 Dr. Morich served as Chief Executive Officer and Chairman of the Executive Board of AM Pharma B.V., a clinical-stage drug development company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including member of the board of management of Bayer AG, head of global product development and head of research and development. Dr. Morich graduated in medical studies at the University of Marburg, Germany. Dr. Morich has over 35 years of experience in the life sciences and health care industries and extensive executive leadership experience, making him well qualified to serve on our board of directors as Chairman.

What is the salary of Frank Morich?

As the Independent Chairman of the Board of Cue Biopharma Inc, the total compensation of Frank Morich at Cue Biopharma Inc is $78,256. There are 10 executives at Cue Biopharma Inc getting paid more, with Anish Suri having the highest compensation of $4,559,810.



How old is Frank Morich?

Frank Morich is 66, he's been the Independent Chairman of the Board of Cue Biopharma Inc since 2020. There are 2 older and 17 younger executives at Cue Biopharma Inc. The oldest executive at Cue Biopharma Inc is Frederick Driscoll, 70, who is the Independent Director.

What's Frank Morich's mailing address?

Frank's mailing address filed with the SEC is C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON, MA, 02135.

Insiders trading at Cue Biopharma Inc

Over the last 7 years, insiders at Cue Biopharma Inc have traded over $1,426,672 worth of Cue Biopharma Inc stock and bought 1,194,685 units worth $5,848,356 . The most active insiders traders include Daniel R Passeri, Aaron G.L. Fletcher oraz Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,162. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth $11,040.



What does Cue Biopharma Inc do?

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci



What does Cue Biopharma Inc's logo look like?

Cue Biopharma Inc logo

Complete history of Frank Morich stock trades at Perspective Therapeutics Inc i Cue Biopharma Inc

Data
#
Firma
 Osoba
Trans.
Transakcja
 Ilość akcji Cena za akcję Łączna cena Ilość akcji po Źródło
27 May 2022 CUE Cue Biopharma Inc Frank Morich
Kupować 28,000 $3.75 $105,000
27 May 2022
28,000 ↗


Cue Biopharma Inc executives and stock owners

Cue Biopharma Inc executives and other stock owners filed with the SEC include: